A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats

  • McEachern J
  • Bingham J
  • Crameri G
 et al. 
  • 42

    Readers

    Mendeley users who have this article in their library.
  • 58

    Citations

    Citations of this article.

Abstract

Nipah virus (NiV) and Hendra virus (HeV) are closely related deadly zoonotic paramyxoviruses that have emerged and re-emerged over the last 10 years. In this study, a subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein from HeV (sGHeV) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Different amounts of sGHeVwere employed and sG-induced immunity was examined. Vaccinated animals demonstrated varying levels of NiV-specific Ig systemically and importantly, all vaccinated cats possessed antigen-specific IgA on the mucosa. Upon oronasal challenge with NiV (50,000 TCID50), all vaccinated animals were protected from disease although virus was detected on day 21 post-challenge in one animal. The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses. © 2008 CSIRO.

Author-supplied keywords

  • CpG
  • Henipavirus
  • Mucosal immunity
  • Subunit vaccine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Jennifer A. McEachern

  • John Bingham

  • Gary Crameri

  • Diane J. Green

  • Tim J. Hancock

  • Deborah Middleton

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free